Diagnostic Center | June 14, 2024
Moderna announces positive Phase 3 efficacy data for next generation COVID-19 vaccine
Higher efficacy was observed in mRNA-1283 compared to Spikevax in adults 18 years of age and older
Higher efficacy was observed in mRNA-1283 compared to Spikevax in adults 18 years of age and older
mRESVIA is Moderna's second approved product and the only RSV vaccine available in single-dose pre-filled syringes
GAAP net loss of $1.2 billion and GAAP diluted EPS of $(3.07)
Announces changes to commercial organization to prepare for multiple product launches in 2024 and 2025
Supply readiness follows months of manufacturing to ensure timely and ample supply
mRNA-1345 demonstrated vaccine efficacy of 83.7% against RSV lower respiratory tract disease, defined by 2 or more symptoms in older adults
India is working towards augmenting health infrastructure and have initiated multiple schemes to strengthen health systems and improve health service delivery
OriCiro's synthetic biology and enzyme technologies will support Moderna's expanding portfolio of therapeutics and vaccines
Moderna and Merck announced mRNA-4157/V940, in combination with KEYTRUDA, demonstrated a 44% reduction in the risk of disease recurrence or death in melanoma patients
Results are the first demonstration of efficacy for an investigational mRNA cancer treatment in a randomized clinical trial
Subscribe To Our Newsletter & Stay Updated
